Bluejay Diagnostics issued a Q1 2026 corporate update reporting $3.7 million in cash and a $1.9 million net loss, with progress in SYMON-II study enrollment and manufacturing readiness for Symphony IL-6 test.
Key takeaways
Approximately 680 patients enrolled in SYMON-II pivotal study as of May 5, 2026, toward 750 target.
Resolved technical issues in Symphony cartridge manufacturing with Sanyoseiko Co. Ltd., advancing validation activities.
Cash and cash equivalents of $3.7 million as of March 31, 2026.
Net loss of approximately $1.9 million for Q1 2026, same as Q1 2025.
Pursuing FDA 510(k) submission for Symphony IL-6 after clinical and analytical validation.